Polsinelli announced today distinguished intellectual property attorney Dr. David W. Clough joined as shareholder in its Chicago office, along with a team that includes another shareholder and an associate. Clough brings more than 25 years of experience to the firm’s growing Intellectual Property Department, which is comprised of more than 120 attorneys, patent agents and scientists coast to coast, and strengthens the firm’s position as a market-leader in providing legal services to the biotech and life sciences communities.
Clough, who holds a Ph.D. in microbiology, provides counsel to many sectors of the biotechnology, medical and pharmaceutical industries. His practice focuses on acquiring and enforcing key intellectual property rights globally. Collaborating with clients on designing and implementing their IP strategies, Clough oversees due diligence analysis in multibillion-dollar acquisitions, prosecutes patent applications and represents clients in IP litigation, arbitration and administrative and regulatory proceedings.
“David is one of the country’s preeminent biotech attorneys. We are very pleased to bring his talent, scientific background and tremendous experience to our growing IP team,” said Intellectual Property Department Chair Patrick Woolley. “We have great momentum in our IP Department right now, and the addition of David, his team, and his depth of expertise enables us to better serve clients in the biotechnology and pharmaceutical sectors, where demand has been particularly high.”
Also joining Polsinelli in Chicago with Clough are patent attorneys Christopher Cabral and John W. Campbell. Cabral joins the firm as a shareholder; Campbell as an associate.
Cabral, also a Ph.D. scientist, provides biotech and life science patent prosecution and counseling to clients around the world, with a particular emphasis on serving the pharmaceutical, diagnostic and chemical industries. He works with clients to successfully manage patent applications in the U.S. and abroad, and to evaluate their patent positions.
Campbell, another Ph.D. scientist, brings his extensive background in bioinformatics, biotechnology, and microbiology research to bear on his patent prosecution and patent counseling services for clients.
Clough taps his legal and scientific backgrounds to prosecute applications and render opinions on patents in the medical arena, including gene therapy, genetic engineering of viruses, cloning and expression of novel proteins, nucleic acid diagnostics, nucleic acid sequencing, transgenic animals, immunotherapy, reproductive technologies, genetic engineering of antibodies, screening methods for identification of drug candidates, novel drug formulations and delivery systems, cancer therapies, food chemistry, steroid chemistry, genetically engineered plants, methods and compositions for treating neurological diseases, and medical devices. His background also informs his litigation, mediation, and arbitration practice, in which he has handled cases involving DNA fingerprinting probes, genetic engineering of antibodies, diagnostic DNA probes, and recombinant proteins, as well as trade secret violations, Lanham Act violations, inventorship disputes, and license disputes.
“Polsinelli’s firm culture fosters innovation and an integrated approach to serving clients,” Clough said, “There’s a great relationship between the healthcare, biotech and life sciences practice areas, coupled with intellectual property and patent prosecution, which gives me great confidence that this is the right place to serve clients’ most sophisticated IP needs.”
Polsinelli has 20 offices nationwide. The additions of Clough, Cabral, and Campbell in Chicago builds to the current growth seen within Polsinelli’s IP team, including other new hires over the past six months in Boston, New York City, Washington D.C., St. Louis, Kansas City, Denver, Los Angeles, San Francisco, and Silicon Valley. Earlier this year, recognizing the increased client focus on IP, Polsinelli announced that it elevated Intellectual Property as a fourth service department to serve alongside Polsinelli’s existing Business, Litigation, and Real Estate, and Financial Services Departments.